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gression. All patients received standard corticosteroid pro-
phylaxis.  Results: Since interim analysis showed failure to 
reach a significant difference for the primary endpoint (he-
matotoxicity, i.e. leukopenia), the study was closed accord-
ing to the study protocol (85 of 242 patients). A lower-than-
expected rate of leukopenia  6 grade 3 was observed in the 
standard arm of the D4 study compared to the weekly sched-
ule (per-patient analysis: 61.9% q3w vs. 65.1% q1w; p  1 0.05). 
Grade 3 and grade 4 fever, diarrhea, and infections occurred 
more frequently in the standard arm, whereas neurotoxicity 
and skin/nail disorders were observed more frequently in 
the weekly arm. Except for fever, none of these differences 
reached a level of significance. Dose delays, dose reductions, 
and the rate of omitted doses were increased in the weekly 
arm. The overall response rate was 44.2% in the weekly arm 
compared to 52.4% in the standard arm (p = 0.52). Time to 
progression was 6.2 (q1w) versus 10.3 (q3w) months (p = 
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 Abstract 
 Purpose: Previous phase II studies have indicated a greatly 
reduced hematotoxicity of docetaxel-based regimens ad-
ministered on weekly schedules. The present trial was initi-
ated to compare the toxicity and efficacy of weekly docetax-
el versus its standard 3-weekly application in combination 
with doxorubicin.  Methods: Patients previously untreated 
with chemotherapy for metastatic disease were recruited. 
Inclusion criteria were age  ! 65 years or a Karnofsky Perfor-
mance Status of 70–100%. All patients in the D4 study re-
ceived doxorubicin (50 mg/m 2 ) on the first day of treatment 
in addition to docetaxel given either at a 3-weekly dose of 75 
mg/m 2 every 3 weeks (q3w) or at a weekly dose of 35 mg/m 2 
(days 1, 8, and 15; q4w). Treatment was continued until a 
maximum of 8 cycles, unacceptable toxicity, or disease pro-
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0.36), and overall survival was 20.5 (q1w) versus 28.7 (q3w) 
months (p = 0.98).  Conclusion: The present data support
the feasibility of both weekly and 3-weekly application of 
docetaxel in combination with doxorubicin. Nevertheless, 
given that leukopenia was similar in both arms and the effi-
cacy parameters were at least numerically inferior with the 
weekly schedule, standard 3-weekly application seems to
be preferable for patients requiring combination chemo-
therapy.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Docetaxel (Taxotere; Sanofi-Aventis, Frankfurt, Ger-
many) is one of the most effective antitumor agents cur-
rently available for the treatment of early breast cancer as 
well as metastatic breast cancer (MBC). In MBC, when 
compared with the gold standard doxorubicin, docetaxel 
has shown a significantly superior response rate (RR; 47.8 
vs. 33.3%; p = 0.008) and a trend towards a prolonged time 
to progression (TTP; 26 weeks vs. 21 weeks)  [1] . After fail-
ure with anthracycline-containing chemotherapy, sin-
gle-agent docetaxel has demonstrated superior results 
when compared with mitomycin/vinblastine [RR, TTP, 
and overall survival (OS)] or methotrexate/5-fluorouracil 
(RR and TTP), and it has shown equivalent efficacy when 
compared with vinorelbine/5-fluorouracil (RR, TTP, and 
OS)  [2–4] .
 When docetaxel is administered at a standard dose of 
100 mg/m 2 [every 3 weeks (q3w)], 70–90% of patients de-
velop grade 3/4 neutropenia  [1] . Instead of dose reductions, 
one strategy to reduce toxicity without growth factor sup-
port is to apply docetaxel on a weekly schedule. Several 
studies have indicated that severe hematotoxicity (grade 
3/4) could largely be prevented at weekly doses of less than 
40 mg/m 2 without impaired efficacy in the first- or second-
line setting  [5–9] . Moreover, the favorable toxicity profile 
of weekly scheduled docetaxel was confirmed in 2 ran-
domized phase II/III trials without inferior results regard-
ing TTP or OS  [10, 11] . A further rationale for weekly do-
cetaxel might be that standard-dose single-agent doce -
taxel (100 mg/m 2 q3w) frequently needs to be adjusted to 
75 mg/m 2 in pretreated, unfit, or elderly patients  [12] .
 The relatively low rate of severe leukopenia associated 
with weekly scheduled docetaxel may permit a combina-
tion with other cytotoxic agents. Taxanes and anthracy-
clines are considered among the most active single agents 
for the treatment of early breast cancer as well as MBC. 
Consequently, their combined use is a logical step in the 
search for highly effective chemotherapy combinations. 
Phase II trials which have investigated such an anthracy-
cline/taxane combination given on a 3-week schedule 
have shown an improved RR of 46–88% without a higher 
rate of cardiotoxicity  [13–16] . The high RR were attained 
in patients with unfavorable prognostic factors (multiple 
metastatic sites, visceral involvement, and prior exposure 
to adjuvant chemotherapy). However, the dose-limiting 
factor in these trials was leukopenia. Phase II trials inves-
tigating a weekly scheduled anthracycline/taxane combi-
nation proved efficient and had a manageable toxicity 
profile  [17, 18] . Considering these prior experiences, the 
D4 study was designed to evaluate the toxicity and effi-
cacy of a weekly docetaxel/doxorubicin regimen com-
pared to a 3-weekly scheduled standard scheme in young-
er and medically fit patients with MBC.
 Patients and Methods 
 Patient Selection 
 The treatment protocol was approved by the local ethics com-
mittee and all patients gave their written informed consent before 
treatment was started. 
 Patients with MBC, none of whom had received chemotherapy 
for metastatic disease, were recruited for the trial. Patients were 
required to have a Karnofsky Performance Status (KPS)  6 70% 
and an age between 18 and 65 years. Patients who had received 
prior adjuvant anthracyclines at a cumulative dose  6 200 mg/m 2 
or who had a positive history of coronary heart disease with car-
diac dysfunction or an impaired left ventricular ejection fraction 
(EF) were not eligible; cardiac EF had to be normal ( 6 50%).
 Patients were required to have histologically proven MBC, bi-
dimensionally measurable disease, and an anticipated survival of 
at least 12 weeks. Prior to study entry, hepatic, renal, and hemato-
logical functions had to be adequate [leukocyte count  6 3.0  ! 
10 9 /l, platelets  6 100  ! 10 9 /l, hemoglobin  6 8 g/dl, bilirubin 
 ^  1.25 times the normal range, alanine aminotransferase:aspar-
tate aminotransferase (ALT:AST) ratio  ^  3 times the normal 
range, and alkaline phosphatase  ^  2.5 times the normal range].
 Patients with bone metastases only and/or steroid (estrogen 
and/or progesterone) receptor expression without prior endo-
crine therapy were not eligible for the trial. Additional exclusion 
criteria were active infections, radiotherapy of more than 25% of 
marrow-containing bone, clinically overt brain metastases, pre-
vious neuropathy  6 grade II, or a history of a second malignancy 
other than resected basal cell and/or squamous cell carcinoma of 
the skin. 
 Patients were not eligible for study enrolment if they were 
pregnant or lactating, or if they refused effective contraception.
 Treatment Regimen 
 Docetaxel was dissolved in 100 ml of 0.9% saline and given by 
intravenous (i.v.) infusion over 30 min (35 mg/m 2 weekly) or 60 
min (75 mg/m 2 q3w), respectively. Doxorubicin (50 mg/m 2 ) was 
dissolved in 250 ml of 0.9% saline and infused for 60 min.
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 Patients in the D4 study received doxorubicin (50 mg/m 2 ) on 
the first day of treatment in addition to docetaxel given either at 
a 3-weekly dose of 75 mg/m 2 q3w or at a weekly dose of 35 mg/m 2 
(days 1, 8, and 15; q4w). Treatment was continued until a maxi-
mum of 8 cycles, unacceptable toxicity, or disease progression.
 All patients received standard corticosteroid prophylaxis, an-
tiemetics (routinely 5HT3 antagonists), and growth factors (which 
were allowed at any point) according to the local standards.
 Dose Adjustments  
 In case of myelosuppression on the day of the planned treat-
ment (leukocytes  ^  2,000/  l and platelets  ^  50,000/  l), further 
drug administration was postponed for 1 week until bone mar-
row recovery occurred (leukocytes  6 2,000/  l and platelets 
 6 50,000/  l). If there was no recovery within the additional rest 
of 1 week, the patient was excluded from the study. A reduced dose 
of each drug (–25%) was applied in case of a leukocyte count
between 2,000/  l and 3,000/  l and a platelet count between 
50,000/  l and 100,000/  l. A full dose of docetaxel and doxorubi-
cin was administered if the blood counts had risen to leukocytes 
 6 3,000/  l and platelets  6 100,000/  l.
 Patients were excluded from the trial in case of nonhemato-
logical toxicity  6 grade 3 (excluding alopecia and nausea/vomit-
ing). Dose reductions of 25% (for doxorubicin and docetaxel) were 
required in case of hematological toxicity grade 3 or 4 compli-
cated by fever, infection, or both. Moreover, a reduced dose (–20%) 
was required in case of grade 3 diarrhea or mucositis.
 Data Collection 
 Drug administration, KPS, and toxicity or adverse events were 
recorded after every cycle of treatment. Weekly blood counts were 
performed. Febrile neutropenia was defined as fever ( 6 38   °   C) 
with grade 4 neutropenia requiring i.v. antibiotics and/or hospi-
talization without documented infection. Fluid retention includ-
ed peripheral edema and/or pleural and pericardial effusions.
 Toxicity was graded according to the National Cancer Insti-
tute’s Common Toxicity Criteria (NCI CTC 2.0)  [19] . Imaging 
studies using ultrasonography, computed tomography (CT), or 
magnetic resonance imaging (MRI) were performed after every 2 
cycles of treatment.
 Cardiac Surveillance 
 Patients in the D4 trial underwent echocardiography prior to 
study entry and then after every second cycle. An EF  6 50% was 
considered normal. Patients were excluded from the study if the 
EF decreased to  ^  50% or decreased by  6 10% compared to the 
baseline value.
 Response Evaluation 
 In all patients, tumors were measured by imaging procedures 
(ultrasound, CT, or MRI) within 14 days prior to study entry and 
subsequently after every 2 cycles of treatment. A standard evalu-
ation comprised of history, a physical examination, and routine 
laboratory tests (including a complete blood cell count, chemistry 
profile, and electrolyte determination) was performed before each 
treatment.
 Patient response was assessed according to standard WHO 
criteria as follows: Complete response (CR) was defined as the 
disappearance of all known disease as determined by 2 observa-
tions not less than 4 weeks apart, while partial response (PR) was 
defined as a decrease of at least 50% in the sum of the products of 
the largest perpendicular diameters of all measurable lesions as 
determined by 2 observations not less than 4 weeks apart. Stable 
disease (SD), lasting at least 6 weeks from the start of the study 
(i.e. the first drug administration), was defined as a  ! 50% de-
crease and a  ! 25% increase in the sum of the products of the larg-
est perpendicular diameters of all measurable lesions. Progressive 
disease (PD) was a  1 25% increase in the size of at least 1 bidimen-
sionally or unidimensionally measurable lesion or the appearance 
of a new lesion. The occurrence of pleural effusion was considered 
a sign of progression if verified by positive cytology. 
 Study Endpoints and Statistics 
 The primary study endpoint was hematotoxicity (leukopenia). 
Assuming grade 3 and grade 4 hematotoxicity rates of 70–95% for 
the standard regimen and 10–20% for the weekly regimen, the 
calculated sample size for the primary endpoint was 40 patients 
(20 for each treatment arm), with a statistical power of 80% using 
a 5% level of significance (Fishers’s exact test).
 An interim analysis was planned in 80 recruited patients (40 
for each treatment arm) for the primary endpoint using   1 = 
0.0052 and   2 = 0.048 as the levels of significance (O’Brien and 
Fleming sequential design).
 For the secondary endpoint (TTP) the calculated sample size 
was 242 patients, with the assumption of the noninferiority of the 
weekly schedule (TTP q3w = 10.3 months and TTP q1w = 9.3 
months) (O’Brien and Fleming sequential design). Sample sizes 
were calculated using NCSS/PASS 2000 software. Further sec-
ondary endpoints were OS and RR. TTP was determined by the 
interval between the initiation of therapy and the first date that 
disease progression was objectively documented. OS was mea-
sured from the date of the start of treatment to the date of death 
from any cause. All patients were included in the (intent-to-treat) 
analysis of TTP and survival. 
 The probabilities of survival and TTP were estimated by
Kaplan-Meier analysis, and confidence intervals for the RR were 
calculated using methods for exact binominal confidence inter-
vals  [20, 21] . 
 Results 
 Patient Characteristics  
 Patients were recruited between July 2001 and August 
2008. Since the scheduled interim analysis showed failure 
to reach statistical significance for the primary endpoint 
in the final analysis, the D4 study was closed before 
achieving its target recruitment (85 of 242 patients). The 
median observation time was 18.7 months (range 0.3–
52.3). The patients’ characteristics are presented in  table 1 .
 Toxicity 
 A summary of the hematological and nonhematologi-
cal toxicities is given in  table 2 . A comparably low rate of 
leukopenia, i.e.  6 grade 3, which was rather similar to the 
one observed in the weekly arm, was observed in the 
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standard q3w arm of the D4 study (per-patient analysis: 
61.9% q3w vs. 65.1% q1w; p  1 0.05) even though the rate 
of grade 4 leukopenia was nearly twice the number in the 
standard arm (38.1% q3w vs. 20.9 q1w). 
 Fever was more frequently observed in the 3-week reg-
imen (21.4% q3w vs. 4.7% q1w; p = 0.03). Moreover, grade 
3 and grade 4 diarrhea and infections occurred more fre-
quently in the standard arm, whereas neurotoxicity (7.0% 
q1w vs. 0% q3w; p  6 0.05) and skin/nail disorders (11.6% 
q1w vs. 0% q3w; p = 0.06) were observed more frequently 
in the weekly arm. Except for fever, none of these differ-
ences reached the 0.05 level of significance. Other nonhe-
matological toxicities ( 6 grade 3) were comparable be-
tween the 2 schedules. 
 The median number of applied cycles was 6 (range 
1–8) for the standard arm and 5 (range 1–8) for the week-
ly arm. The median duration of treatment was 105.5 days 
(range 1–170) for the standard arm and 151 days (range 
1–245) for the weekly schedule. Dose reductions and de-
layed and omitted doses within a cycle were required sig-
nificantly more often in patients randomized to weekly 
docetaxel (p  ! 0.001, each). There was a significant dif-
ference regarding the percentage of the intended drug de-
livered within a cycle between the 2 regimens (99.2% 
standard dose vs. 78.3% weekly dose).
 Efficacy 
 The overall RR was 48.2% (95% CI 37.3–59.3), with
3 CR, 38 PR, 22 SD, and 15 PD (intent-to-treat analysis) 
( table 3 ). Seven patients were not evaluable. The overall 
RR was comparable between the groups of standard or 
weekly scheduled docetaxel (44.2% q1w vs. 52.4% q3w;
p = 0.52). Moreover, there was a numerical but not sig-
nificant difference with regard to TTP (6.2 months q1w 
vs. 10.3 months q3w; p = 0.36) and OS (20.5 months q1w 
vs. 28.7 months q3w; p = 0.98) ( table 4 ;  fig. 1 ). A sum-
mary of the response and survival data is given in  tables 
3 and  4 and in  figure 1 .
 Discussion 
 Numerous phase II studies have shown a considerably 
reduced hematotoxicity, but stable efficacy, of weekly 
scheduled docetaxel in the first- or second-line setting of 
MBC  [5–9] . These data have been confirmed in 2 ran-
domized phase II/III trials by Rivera et al.  [10] and Ta-
bernero et al.  [11] . This rather low rate of severe leukope-
nia associated with weekly scheduled docetaxel may per-
mit its combination with anthracyclines. Both agents are 
considered among the most active single agents for the 
treatment of MBC. Consequently, their combined use is 
a logical step in the search for highly effective chemo-
therapy combinations. 
 Previous phase II trials investigated a 3-week sched-
uled anthracycline/taxane regimen with impressive high 
RR of 46–88%  [13–16] . However, the dose-limiting factor 
in these trials was leukopenia, leading to the initiation of 
phase II trials investigating a weekly anthracycline/tax-
ane combination. Such studies have demonstrated effi-
cacy with a manageable toxicity profile  [17, 18] . Gamucci 
et al.  [17] reported a considerably low rate of  6 grade 3 
neutropenia of 16% of patients who received first-line 
weekly epirubicin (25 mg/m 2 ) and docetaxel (25 mg/m 2 ) 
for MBC. The regimen was quite effective, with an RR of 
Table 1.  Patient characteristics
Characteristics D4 (n = 85)
q1 w q3w
Patients 43 42
Age, years
Median
Range
54
29–70
56
39–70
KPS, %
Median
Range
90
70–100
90
70–100
Estrogen and progesterone receptor status
Positive
Negative
Unknown
32
10
1
31
8
3
Menopausal status
Premenopausal
Postmenopausal
11
32
7
35
HER-2 status
Positive (IHC 3+ or 2+ and FISH+)
Negative (IHC 0 or 1+ or 2+ and FISH–)
Unknown
10
22
11
11
26
5
Measurable disease sites
Lung
Liver
Lymph nodes
Skin
Skeleton
20
21
22
4
21
14
23
15
2
15
Disease sites per patient, n
1
2
≥3
9
11
23
13
18
11
Prior treatment
Adjuvant chemotherapy
(including anthracyclines)
Adjuvant hormonal therapy
20
11
23
20
7
22
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60% and a median OS of 25 months. Moreover, Perez-
Manga et al.  [18] reported on a phase II study which in-
vestigated a combination of doxorubicin (50 mg/m 2 q4w) 
and weekly scheduled docetaxel (36 mg/m 2 days 1, 8, and 
15; q4w) for locally advanced or metastatic breast cancer 
(first line). A consistently low rate of severe neutropenia 
( 6 grade 3) was reported ( ! 10% febrile neutropenia) and 
RR were considerably high among locally advanced and 
metastasized patients, i.e. 93 and 64%, respectively.
 Lacking randomized data, the D4 study was designed 
to evaluate the toxicity and efficacy of a weekly docetaxel/
doxorubicin regimen compared to the 3-weekly standard 
scheme in younger and medically fit MBC patients.
 In brief, in the primary safety endpoint of the D4 study 
a significant difference was not reached. The assumption 
of a markedly reduced hematotoxicity within the weekly 
schedule was not verified. Surprisingly, the rate of leuko-
penia ( 6 grade 3) was rather low in the standard arm, 
whereas it was not reduced at all in the weekly arm (61.9% 
q3w vs. 65.1% q1w; p  1 0.05). Since the primary endpoint 
was not reached, the D4 study was closed after an inter-
im analysis according to the study protocol (85 of 242 
Table 3.  Efficacy: RR (intent-to-treat analysis)
D4 CR PR SD PD Not evaluable RR, % 95% CI, % p
All patients (n = 85) 3 38 22 15 7 48.2 37.3–59.3
q1w group (n = 43) 1 18 9 10 5 44.2 29.1–60.1 0.52aq3w group (n = 42) 2 20 13 5 2 52.4 36.4–68.0
a  RR q1w versus q3w.
Table 2.  Toxicity profile (per-patient analysis): hematological and nonhematological toxicity by NCI CTC grade
A (q3w), % B (q1w), % p value (after
dichotomiza-
tion ≤2/≥3)0 1 2 3 4 0 1 2 3 4
Hematological toxicity
Anemia 14.3 57.1 28.6 0 0 11.6 44.2 34.9 9.3 0 >0.05
Leukopenia 11.9 4.8 21.4 23.8 38.1 11.6 9.3 13.9 44.2 20.9 >0.05
Thrombocytopenia 71.4 21.4 4.8 2.4 0 58.1 27.9 6.9 6.9 0 >0.05
Nonhematological toxicity
Alopecia 14.3 7.1 78.6 0 0 18.6 9.3 72.1 0 0 >0.05
AP 61.9 35.7 2.4 0 0 62.8 32.6 4.7 0 0 >0.05
Arrhythmias 85.7 9.5 4.8 0 0 90.7 4.7 2.3 2.3 0 >0.05
Bilirubin 97.6 0 2.4 0 0 81.4 16.3 0 2.3 0 >0.05
Constipation 57.1 35.7 7.1 0 0 79.1 9.3 9.3 2.3 0 >0.05
Creatinine 95.2 2.4 0 2.4 0 88.4 11.6 0 0 0 >0.05
Diarrhea 50.0 30.9 14.3 2.4 2.4 65.1 23.3 11.6 0 0 >0.05
Fever 61.9 4.8 11.9 21.4 0 72.1 11.6 11.6 4.7 0 0.03
Fluid retention 76.2 16.7 4.8 2.4 0 69.8 18.6 11.6 0 0 >0.05
Gastrointestinal symptoms 90.5 4.8 2.4 2.4 0 95.4 2.3 2.3 0 0 >0.05
GGT 42.9 26.2 14.3 14.3 2.4 46.5 20.9 6.9 20.9 4.7 >0.05
Infections 50.0 14.3 19.1 11.9 4.8 69.8 6.9 18.6 4.7 0 >0.05
Mucositis 50.0 26.2 16.7 7.1 0 34.9 27.9 27.9 9.3 0 >0.05
Musculoskeletal disorders 97.6 0 2.4 0 0 95.4 4.7 0 0 0 >0.05
Nausea and vomiting 30.9 40.5 19.1 7.1 2.4 53.5 20.9 13.9 11.6 0 >0.05
Neurotoxicity 61.9 28.6 9.5 0 0 55.8 23.3 13.9 4.7 2.3 >0.05
Edema 100.0 0 0 0 0 93.0 0 6.9 0 0 >0.05
Pain 35.7 35.7 21.4 2.4 4.8 62.8 16.3 18.6 2.3 0 >0.05
Skin and nail disorders 85.7 9.5 4.8 0 0 60.5 18.6 9.3 9.3 2.3 >0.05
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patients). The presumption of a greatly reduced hemato-
toxicity in the weekly arm was based on the studies of 
Perez-Manga et al.  [17] and Gamucci et al.  [18] . Both in-
vestigated a weekly scheduled anthracycline/taxane com-
bination which has shown a reduced rate of leukopenia. 
Thus, we cannot provide a valuable explanation for the 
relatively high numbers of grade 3 and 4 leukopenia in 
the weekly docetaxel arm observed in our study. 
 With regard to nonhematological toxicities, i.e. skin 
and nail disorders, the known sequelae of weekly admin-
istered docetaxel were increased in patients who were 
randomized to the weekly schedule (11.6% q1w vs. 0% 
q3w; p = 0.06). Moreover, even more surprisingly, the rate 
of reduced, delayed, or omitted doses within a cycle was 
significantly higher among patients receiving weekly 
docetaxel as follows: 38.3 versus 23.3%, 31.1 versus 10.6%, 
and 21.9 versus 0%, respectively (q1w vs. q3w; p  ! 0.001, 
each). Therefore, the percentage of the intended drug de-
livered within a cycle was greatly reduced in the weekly 
arm (77.3% q1w vs. 90.3% q3w) ( table 5 ).
 It is suspected that this lesser dose contributed to a 
measurable loss of efficacy even though none of the dif-
ferences in RR, TTP, and OS reached the level of signifi-
cance. The RR was 44.2% in the weekly arm compared to 
52.4% under the standard regimen (p = 0.52). Moreover, 
the median TTP and OS were numerically inferior in pa-
tients who received the weekly schedule. TTP was 6.2 
(q1w) versus 10.3 (q3w) months (p = 0.36), and OS was 
20.5 (q1w) versus 28.7 (q3w) months (p = 0.98). 
 A final statement regarding efficacy is restricted by the 
limitation that the calculated sample size for the second-
ary endpoints (TTP and OS) was not reached in the D4 
study. Moreover, imbalances regarding the cumulative 
anthracycline dose between both study arms may con-
tribute to a bias regarding the efficacy parameters (50
mg/m 2 doxorubicin applied q3w in the ‘standard arm’ vs. 
q4w in the ‘weekly arm’). Nevertheless, the study was ter-
Table 5.  Toxicity profile: dose modifications
All q3w q 1w p value
(n = 432) (n = 236) (n = 196)
Cycles
Dose reductionsa 130 (30.09) 55 (23.31) 75 (38.27) <0.001
Delayed dosesa 86 (19.91) 25 (10.59) 61 (31.12) <0.001
Omitted dosesa 43 (9.95) 0 43 (21.94) <0.001
Percentage of intended
drug delivery 84.29 90.25 77.30 <0.001
a R eductions within a cycle; data given as n (%).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 180 360 540 720 900 1,080 1,260 1,440
 D4: median OS
q3w 28.7 mo
q1w 20.5 mo
p = 0.98 
D4: median TTP
q3w 10.3 mo
q1w 6.2 mo
p = 0.36
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n 
of
 T
TP
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nd
 s
ur
vi
va
l
Time (days) Fig. 1. TTP and OS in the D4 study. mo = 
Months. 
Table 4.  Efficacy: TTP and OS
D4 q3w q 1w p value
(log-rank 
test)median range median range
TTP, months 10.3 1.3–23.8 6.2 0.2–30.5 0.36
OS, months 28.7 0.4–37.9 20.5 0.3–46.8 0.98
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minated after the interim analysis due to failure to reach 
statistical significance in the primary endpoint (leukope-
nia). The striking trend towards an improved TTP and 
OS within the standard arm of the D4 study (q3w vs. q1w: 
TTP 10.3 vs. 6.2 months and OS 28.7 vs. 20.5 months) 
may be – at least partially – explained by the above men-
tioned limitations.
 In conclusion, the data of the D4 study have surpris-
ingly but unmistakably shown that leukopenia could not 
be prevented by a weekly schedule of a docetaxel/anthra-
cycline combination despite phase II data indicating a 
greatly reduced hematotoxicity in favor of the weekly 
administration of docetaxel. In view of the at least nu-
merically reduced efficacy in the weekly arm as well as 
the substantially increased nonhematological side ef-
fects, this approach seems not to merit further investiga-
tion.
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